Hypertension in Hemodialysis Patients (Aim 3)
Stopped early · Phase 3
Conditions studied: Hemodialysis, Hypertension, Left Ventricular Hypertrophy
In brief
We will directly test the hypothesis that an initial strategy of lisinopril-based therapy will be more effective than atenolol-based therapy in causing regression of left ventricular hypertrophy (LVH) over one year in patients with hemodialysis hypertension despite similar degree of BP reduction.
Key facts
- Study ID
- NCT00582114
- Run by
- Indiana University
- People needed
- 200
- Starts
- 2005-08-01
- Expected to finish
- 2013-09-01
- Last updated by the study team
- 2016-01-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients on chronic hemodialysis for > 3 mos.
- Compliance with hemodialysis treatments as defined by less than one missed dialysis per month
- Hypertension as diagnosed by ambulatory blood pressure monitoring (ABPM) >135/75 mm Hg after participation in the ultrafiltration (UF) Trial, or those on no antihypertensive medications but unwilling to do UF Trial.
- Presence of LVH on echocardiogram defined as left ventricular mass index (LVMi) >104 g/m2 in women and >116 g/m2 in men.
- Willingness to give informed consent.
You may not qualify if…
- Vascular event (stroke, myocardial infarction or limb ischemia requiring bypass) within previous six months
- Noncompliance with hemodialysis treatments
- Known drug abuse
- Chronic obstructive pulmonary disorder (COPD) requiring home oxygen
- Congestive Heart Failure Class III or IV.
- Body mass index > 40 kg/m2.
- Known contraindication to atenolol (severe heart failure, bradycardia, bronchial asthma, intolerance or allergy) or lisinopril (cough, pregnancy, intolerance or allergy)
Where it is running
- Indiana University — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.